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Abstract 
 
Background: Microsampling techniques are alternative methods to venous 
sampling for obtaining blood for measurement of circulating biomarkers, 
offering the convenience of reduced sample volume and elimination of the 
need for phlebotomists. Dried blood spot (DBS) microsampling methods have 
been used for many years while more recently a volumetric absorptive 
microsampling device (VAMS™) has been introduced. In diabetes mellitus, 
circulating C-peptide is commonly used as an indicator of endogenous insulin 
secretion and clinical measurement can aid in diagnosis as well as informing 
on therapy. This pilot study investigated the effectiveness of microsampling 
collection of capillary blood for measurement of C-peptide. 
Methods: Capillary blood was collected into capillary tubes and centrifuged 
for plasma samples. Simultaneous samples were also collected using both 
microsampling methods (DBS and VAMS). Blood from both microsamplers 
was extracted prior to assaying for C-peptide alongside the corresponding 
plasma samples, using specific immunoassays and results obtained from 
microsampling compared to the reference plasma concentrations. Stability 
was determined by collecting duplicate DBS and VAMS and assaying both in a 
single assay after storing one at -20°C immediately and one at room 
temperature for 48 hours post-collection. 
Results: Good agreement was observed between C-peptide concentrations in 
plasma and equivalent DBS and VAMS samples (R2 0.929 and 0.9231; DBS and 
VAMS respectively), with mean differences of 75.7 and 8.4pmol/L observed 
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for DBS and VAMS. Small decreases in C-peptide of 11.6% and 0.1% were 
observed after 48hours storage for DBS and VAMS respectively. 
Conclusions: C-peptide collected using DBS and VAMS showed good 
agreement with reference plasma concentrations, suggesting both would be 
an effective microsampling method for collection and measurement of C-
peptide.  
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INTRODUCTION 
Use of microsampling techniques eliminates the need for large blood volume 
collection for the determination of circulating blood concentrations of 
biomarkers and drugs and in particular can be highly beneficial and 
convenient when monitoring young children and the elderly. Dried blood 
spot (DBS) collection has been an established method in blood analysis for 
many years, due to the elimination of the need for a phlebotomist and 
centrifugation step, lower blood volume and ease of transport (e.g. postage). 
DBS collection, however, may be limited by factors including haematocrit, 
blood viscosity, inaccuracy of sample volume, sampling conditions, sampling 
quality and the nature/stability of analytes [1]. A novel volumetric absorptive 
microsampling (VAMS™) device, consisting of an absorptive, fixed volume 
sampling pad attached to a plastic stem, has recently become available that 
reportedly is not affected by haematocrit levels [2] or sampling conditions as 
it collects accurate, reproducible fixed sample volume.  
In subjects with diabetes mellitus, plasma or serum C-peptide is commonly 
used as a measure of endogenous insulin secretion as both insulin and C-
peptide are co-secreted in equimolar amounts [3].  As approximately half of 
the insulin secreted by the pancreas is metabolised by the liver, 
measurement of peripheral C-peptide, which does not undergo hepatic 
extraction, rather than peripheral insulin allows a more accurate indication of 
insulin secretion. Unlike insulin, the rate of C-peptide clearance in the 
peripheral circulation is at a constant rate, giving more accurate and 
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consistent measurements. Measurement of C-peptide also avoids potential 
issues of cross-reactivity between exogenous and endogenous insulin in 
insulin assays [4,5].   
As well as denoting endogenous insulin production, C-peptide has also been 
shown to change with the age of diagnosis, the type (Type 1 or Type 2) and 
duration of diabetes [6]. Clinical measurement of C-peptide in diabetes can 
therefore aid in the diagnosis, prognosis and therapeutic response [4,7]. It 
has previously been identified that measuring C-peptide collected using DBS 
can be used as a first line screening test monitoring beta cell function [1], 
with DBS correlating well with plasma levels [8].  
This study aimed to provide pilot data to inform the effectiveness of both 
DBS and a novel VAMS device for collection of capillary finger-prick samples 
for measuring C-peptide concentrations. 
METHODS 
 
Sample collection  
 
Capillary blood samples were collected via finger-prick from adult staff 
volunteers at the Diabetes Research Unit Cymru, following informed consent. 
Fasting and postprandial samples were collected to ensure a wide C-peptide 
concentration range. All samples were disposed immediately following 
analysis. 
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Approximately 100µl capillary blood, collected into EDTA capillary tubes 
(Sarstedt, UK), was centrifuged at 4,000rpm for two minutes and plasma 
removed. Plasma samples were frozen at -20°C until assayed. 
A further 25µl blood was collected onto a 226 Spot Saver RUO Card 
(PerkinElmer, UK). Samples were left to dry for at least 1 hour at room 
temperature, then 6mm spots were punched from the card and placed in 
sealable plastic bags with desiccant. 
Either 10µl or 20µl of blood was also collected onto Mitra® VAMS devices 
(Neoteryx, USA), by placing the sampling tip to the blood sample and allowing 
the tip to fully turn red. Following this, the device was transferred to a plastic 
‘clamshell’ storage package and left to dry at room temperature overnight.  
  
Blood Extraction 
 
DBS 
The 6 mm spots punched from the DBS card were added directly to the assay 
microplate wells. No extraction was carried out beforehand.  
 
VAMS device 
Prior to assay, the VAMS tips were removed from the device and placed into a 
mini spin column (EZ-10, Biobasic, Canada) at room temperature in either 
140µl antibody conjugate (chemiluminescence assay) or 110µl assay buffer 
(ELISA). Assay method details are given below. Spin columns were incubated 
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at room temperature while shaking (900rpm) for one hour and then 
centrifuged at 13,000rpm for three minutes. The supernatant was transferred 
into 1.5ml microtubes until assayed.    
 
 
Assay protocols  
The reference method of determining C-peptide was a sensitive 
chemiluminescence assay (IV2-004, Invitron, UK). To establish if the extraction 
method was transferable to alternative assay formats, an ELISA (10-1136-01, 
Mercodia, Sweden) was also performed on a smaller number of samples.  
Chemiluminescence assay 
Manufacturer’s protocol was followed for measuring from both plasma and 
DBS. Briefly, 100µl labelled antibody (a soluble antibody labelled with a 
chemiluminescent acridinium ester) was added to each well followed by 
either 25µl standard, quality control, plasma sample or a single DBS. For 
measuring from the VAMS device, a slight adaptation to this protocol was 
made; 125µl extracted blood in antibody conjugate (extraction described 
above) was added directly to the assay well.  
The plate was then incubated at 37°C for two hours, washed and read 
immediately on a plate luminometer (Berthold Centro LB960).  
ELISA 
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Manufacturer’s protocol was followed for measuring plasma and DBS; 25µl 
standard, quality control, plasma sample or a single DBS was added to each well 
followed by 50µl assay buffer. For measuring from the VAMS device, 75µl extracted 
blood in assay buffer (as described above) was added. The plate was then incubated 
at room temperature on a shaker for an hour and washed. Antibody conjugate 
(100µl) was then added to all assay wells, incubated for a further hour at room 
temperature on a shaker before being washed. TMB (200µl) was added to the assay 
wells and incubated for 15 minutes at room temperature before adding 50µl stop 
solution. The plate was read immediately on a Multiskan™ GO Microplate 
Spectrophotometer (Thermo, UK) at 450nm.  
 
Mikrowin 2000 curve fitting software (MikroWin ver. 4.29. Mikrotek 
Laborsysteme GmbH) was used to obtain C-peptide concentrations from 
luminometer or spectrophotometer outputs.   
 
Plasma equivalent correction factors  
A correction factor (CF) for extracted samples was employed to give plasma 
equivalent values, in order to account for the use of whole blood and for 
differences in blood volumes used in the assays.  
DBS 
Due to the nature of DBS, a variable volume of blood may be collected so a 
consistent theoretical equation could not be calculated. Analysis via 
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regression equation comparing plasma and DBS gave a plasma equivalent CF 
of 4.3. 
VAMS 
The following factors were taken into consideration when calculating the CF 
for VAMS: Use of whole blood (*0.5 for plasma); VAMS sample volume vs. 
25µl plasma assay volume (*0.4 [10µl VAMS] or *0.8 [20µl VAMS]); Volume of 
total extracted sample added to assay well (*0.89 [125ul of 140ul in 
chemiluminescence assay] or *0.68 [75µl of 110µl in ELISA]). This generated a 
theoretical plasma equivalent CF of 5.6 and 2.8 for the chemiluminescence 
assay (10µl and 20µl VAMS, respectively) and 7.35 and 3.67 for the ELISA 
(10µl and 20µl VAMS, respectively). Theoretical CFs were confirmed using 
linear regression equation comparing VAMS and plasma results.  
 
Statistical Analysis 
Linear regression analysis was used to evaluate the relationship between 
plasma and DBS or VAMS C-peptide levels. Comparison of blood collection 
methods against the plasma reference, assayed using the chemiluminescence 
assay was displayed using Bland Altman plots and analysed using Passing-
Bablok analysis to identify any constant or proportional bias.    
 
RESULTS 
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Plasma comparison 
The relationship between plasma C-peptide concentrations and plasma 
equivalent DBS and VAMS concentrations, measured using the 
chemiluminescence assay is shown in Fig 1. Good overall agreement was 
observed between plasma and plasma equivalent C-peptide concentrations 
collected using either DBS (R2 0.929, P<0.0001; y=1.1468X – 133.55) or VAMS 
(R2= 0.9231, P=0.0001; y=1.0024x – 10.198). No constant or proportional bias 
was observed.  
 
 
 
 
Figure 1. Relationship between plasma C-peptide and DBS (closed circles, solid 
regression line) or VAMS (open circles, dashed regression line) plasma 
equivalent C-peptide concentrations measured in the chemiluminescence 
assay. 
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Difference (Bland Altman) plots for plasma and plasma equivalent C-peptide 
concentrations are shown in Fig 2. Mean differences of 75.7pmol/L (2.8%) 
and -8.4pmol/L (-3.0%) were observed for DBS and VAMS respectively.  
 
Figure 2. Difference plots for plasma C-peptide vs. plasma equivalent (a) DBS 
and (b) VAMS C-peptide concentrations assayed using chemiluminescence 
assay. 
 
Stability 
Stability at room temperature was determined by collecting two DBS and two 
VAMS samples per subject. One sample of each collection method was stored 
at -20 °C immediately (baseline), while a second sample was stored at room 
temperature for 48 hours, and then stored at -20 °C until assay. After 
allowing samples to reach room temperature, all were extracted and 
analysed in the same assay.  Mean (SD) baseline C-peptide concentrations of 
992 (747) pmol/L and 1280 (1459) pmol/L were observed for DBS and VAMS 
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respectively. Decreases of 11.6% and 0.1% were observed after 48 hours 
storage at room temperature for DBS and VAMS respectively.  
 
Reproducibility  
DBS and VAMS finger prick blood samples (n=2, collected in triplicate) were 
collected and dried overnight, before extraction and analysis in a single assay. 
Mean coefficients of variation of 26.4% and 4.3% were observed for DBS and 
VAMS respectively. 
 
DISCUSSION 
The objective of this pilot study was to evaluate whether capillary blood 
samples collected using either dried blood spots or a novel volumetric 
absorptive micro-sampling device can provide an accurate measurement of 
C-peptide compared to a reference plasma sample. Both microsampling 
methods offer greater convenience over venous samples; samples can be 
transported without dry ice or biohazard needs, do not require immediate 
sample processing upon collection and use a direct sampling approach via 
finger prick, eliminating the need for a nurse or phlebotomist. Previous bio-
analytical studies measuring alternative analytes show VAMS (Mitra devices) 
perform better than conventional DBS sampling in terms of stability and 
reproducibility (9,10).   
 
We identified that both DBS and VAMS showed good agreement in the 
measurement of C-peptide when compared with their corresponding plasma 
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results with little or no bias; supporting work by Willemsen et. al (2016) who 
have previously shown good correlation (R=0.95) between plasma C-peptide 
and levels of C-peptide from  samples collected by DBS [8].  
 
Microsampling has the advantage of being able to be collected at home and 
transported to a lab through the postal system; therefore stability of the 
analyte of interest at ambient temperature is critical to its usefulness. 
Numerous studies have shown C-peptide to be stable when collected using 
DBS for up to 7 days when stored at room temperature, with Johansson et al 
(2010) identifying that C-peptide was stable for 6 months on DBS in these 
conditions (1,11,12). No work has yet been published on C-peptide stability 
on VAMS devices specifically, however, in a small number of samples we 
identified that C-peptide collected using VAMS devices proved to be more 
stable than samples collected using DBS, with C-peptide levels remaining 
constant in VAMS after 48 hours storage at room temperature compared to a 
drop of 11% for DBS. This difference could potentially be in part be due to the 
greater variation observed with DBS.  
 
We found that the VAMS device gave more reproducible C-peptide results 
than DBS, with a mean CV% of 4.3% compared to 26.4%, when tested in 
triplicate on the same samples. This could be due to the more accurate 
absorption of the VAMS device, independent of haematocrit levels, 
compared to the potential variable volume collection of DBS. The ease of use 
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of the Mitra could also play a role in the accuracy of collection and reduce the 
need for repeat sampling.    
 
The main limitation of this study is the relatively small sample size. Although 
the sample numbers analysed were less than would be recommended by 
guidelines, the encouraging results would justify performing a full method 
comparison study.  
 
CONCLUSIONS 
In this small pilot study, measurement of C-peptide in capillary blood 
collected onto DBS and a novel VAMS device, showed good agreement with a 
reference plasma C-peptide concentration. The VAMS device showed less 
bias, albeit in a larger number of samples, was more reproducible and 
displayed better stability than corresponding DBS collected samples.  Both 
DBS and VAMS show promise as an effective method for the convenient 
collection of samples in the measurement of C-peptide, and the findings 
warrant further analysis in a larger, more formal method comparison study. 
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